Vertical: CNMBase Year: 2025
Market Size (2025)
$279.21M
Projected (2032)
$538.94M
CAGR (2022–2032)
9.9%
Key Players
10+
Market Overview
The global Bacillus velezensis market was valued at USD 279.21 Million in 2025 and is projected to reach USD 538.94 Million by 2032, expanding at a CAGR of 9.84% during 2026–2032. Over the historic period the market grew from USD 209.79 Million in 2022 to USD 253.90 Million in 2024, and the forecast implies an absolute increase of USD 259.73 Million between 2025 and 2032, almost doubling the 2025 market value.
Bacillus velezensis is a plant-associated, endospore-forming bacterium that has become one of the most widely used active organisms in agricultural biologicals. Its commercial value rests on a combination of traits: the production of antifungal and antibacterial lipopeptides (surfactin, iturin/bacillomycin D and fengycin) and polyketides, efficient root colonisation, induction of systemic resistance in the host plant, and plant-growth-promoting activity. Because the bacterium forms heat- and desiccation-tolerant spores, it can be produced by industrial fermentation and formulated into shelf-stable powders, liquids and granules, which allows it to move through the same distribution channels as conventional crop protection products.
Demand is being shaped by tighter regulation of synthetic fungicides, maximum residue limit (MRL) requirements in export-oriented horticulture, the expansion of certified organic and residue-managed production, and the integration of biologicals into seed-treatment and in-furrow programmes for broad-acre crops. Large crop protection companies now hold B. velezensis-based products in their portfolios, while specialist biological companies continue to commercialise proprietary strains in regional markets.
Key Findings
Formulation: Wettable Powder is the largest segment with a 45.0% share in 2025 (USD 125.64 Million), while Liquid is the fastest-growing formulation at a CAGR of 11.04% during 2026–2032.
Crop Type: Fruits & Vegetables account for 50.0% of 2025 market value (USD 139.60 Million); Cereals & Grains is the fastest-growing crop type at a CAGR of 10.48%.
Application Method: Soil Treatment leads with a 45.0% share (USD 125.64 Million in 2025), whereas Seed Treatment records the highest CAGR of 11.40%.
Region: North America is the leading region, accounting for 33.0% of the global market in 2025 (USD 92.14 Million). Asia Pacific is the fastest-growing region with a CAGR of 12.10%.
Country: The U.S. is the largest country market at USD 71.87 Million in 2025 (25.7% of the global market). India is the fastest-growing country, with a CAGR of 13.95% during 2026–2032.
Segmentation Summary
The market is analysed by formulation (Wettable Powder, Liquid, Granules), crop type (Fruits & Vegetables, Cereals & Grains, Others), application method (Soil Treatment, Seed Treatment, Foliar) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), with country-level estimates for 20 countries and country groups.
Powder formulations retain the largest share because of their long shelf life, lower logistics cost and established use in soil drench and nursery applications, but liquid formulations are gaining share as manufacturers develop concentrated suspensions that are compatible with liquid fertilisers, seed-treatment slurries and drip irrigation. High-value horticulture remains the core end use, as fruit and vegetable growers face the strictest residue requirements and the highest disease pressure; however, the faster growth of Cereals & Grains reflects the gradual adoption of biological seed and in-furrow treatments on broad-acre crops. Seed Treatment is the fastest-growing application method, supported by seed companies and crop protection majors that combine B. velezensis with chemical or other biological actives in on-seed and at-planting products.
Competitive Landscape Summary
The market is moderately fragmented. Global agricultural input companies such as BASF, Bayer, Syngenta Group, FMC and Novonesis participate through Bacillus-based biofungicides and seed-treatment products, and their distribution reach gives them a strong position in North America and Europe. Specialist biological companies, including Certis Biologicals, ProFarm (Bioceres Crop Solutions), Koppert, Biotrop and ABiTEP, compete with proprietary strains, crop-specific positioning and close agronomic support. Recent activity has been dominated by acquisitions of biological businesses and product rights, new registrations of B. velezensis strains, and launches of combination products for seed and in-furrow use.
Challenges and Opportunities
The principal challenges are variable field efficacy under different soil and climatic conditions, the need for cold-chain or stability management in some liquid formulations, the cost and duration of microbial registration dossiers, and limited grower awareness in emerging markets. Taxonomic reclassification of several commercial strains, historically registered as B. amyloliquefaciens or B. subtilis, also complicates labelling and regulatory comparison across countries. Opportunities lie in seed-treatment and in-furrow combinations for broad-acre crops, liquid formulations compatible with fertiliser programmes, the expansion of biological crop protection in Asia Pacific and Latin America, and regulatory frameworks that have been updated specifically for micro-organisms in the European Union and for bio-inputs in Brazil.
Future Outlook
The market is expected to grow faster than the overall crop protection market through 2032, as biologicals move from niche organic use into mainstream integrated pest management programmes. Growth will be broad-based: all three formulations, crop types and application methods are projected to grow at CAGRs between 8.43% and 11.40%. Regionally, Asia Pacific (12.10%), Middle East & Africa (11.32%) and Latin America (10.85%) will outpace the global average of 9.84%, gradually reducing the share held by North America. Companies that combine robust strains with stable formulations, broad registrations and agronomic evidence on major crops will be best placed to capture this growth.
The Bacillus Velezensis Market market is projected to grow at a CAGR of 9.9% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Bacillus velezensis is a Gram-positive, aerobic, rod-shaped, endospore-forming bacterium of the Bacillus subtilis species complex. The species was first described in 2005 from isolates collected from the Vélez River in Spain. Subsequent genome-based taxonomy established that Bacillus amyloliquefaciens subsp. plantarum and Bacillus methylotrophicus are later synonyms of B. velezensis, which brought a large group of plant-associated biocontrol strains, including the model strain FZB42, under this species name. Several commercial strains that were originally registered as B. amyloliquefaciens or B. subtilis have since been assigned to B. velezensis on the basis of whole-genome comparisons.
For the purpose of this study, the Bacillus velezensis market comprises the value of commercial agricultural products in which one or more B. velezensis strains are a declared active ingredient, including strains registered under earlier taxonomic names that are now recognised as B. velezensis. These products are used as biofungicides, biobactericides, bionematicides and plant-growth-promoting or biostimulant inoculants on crops.
Included: wettable powder, liquid and granular formulations of B. velezensis; products applied through soil treatment (drench, in-furrow, drip and transplant applications), seed treatment and foliar spraying; use on fruits and vegetables, cereals and grains and other crops (including oilseeds, pulses, sugarcane, cotton, turf and ornamentals); and combination products in which B. velezensis is a declared active ingredient alongside other biological or chemical actives.
Excluded: products based on other Bacillus species (for example B. thuringiensis, B. licheniformis or B. subtilis sensu stricto) where B. velezensis is not a declared active ingredient; animal feed probiotics, aquaculture, human probiotic and industrial enzyme applications of the species; and research-grade cultures sold by culture collections. Market value is measured at manufacturer selling prices.
Scope of the Study
The study covers the global market for Bacillus velezensis-based agricultural products, segmented as follows:
By Formulation: Wettable Powder, Liquid, Granules
By Crop Type: Fruits & Vegetables, Cereals & Grains, Others
By Application Method: Soil Treatment, Seed Treatment, Foliar
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
The report provides historic data for 2022–2024, uses 2025 as the base year and presents forecasts for 2026–2032. All market values are expressed in USD Million, and growth rates are presented as compound annual growth rates (CAGR) for 2026–2032.
Research Objectives
To estimate the size of the global Bacillus velezensis market in value terms for 2022–2025 and forecast it to 2032.
To analyse the market by formulation, crop type and application method, and to identify the segments with the largest share and the highest growth.
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
To identify the drivers, restraints, opportunities, trends and challenges influencing the adoption of B. velezensis-based biofungicides and biostimulants.
To examine the regulatory frameworks governing the registration of microbial plant protection products and bio-inputs in key regions.
To evaluate the value chain from strain discovery and fermentation through formulation, distribution and end use.
To profile the competitive environment, including the positioning of leading companies and recent launches, acquisitions, partnerships and registrations.
To provide a forward-looking view of the market to support strategic planning by manufacturers, distributors, investors and policymakers.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured research process that combines secondary research, primary research and analytical modelling. The process began with defining the market scope and segmentation, followed by the collection of information on registered B. velezensis products, manufacturers, crop areas, biological input adoption and regulatory approvals. Market size estimates were developed using both top-down and bottom-up approaches, validated through primary interviews with industry participants, and triangulated to arrive at final values. Forecasts were then developed using a factor-based model that reflects the demand, supply and regulatory drivers specific to agricultural biologicals.
Stage 1 – Scoping: definition of the product, inclusion and exclusion criteria, and segmentation framework.
Stage 2 – Data collection: secondary research and primary interviews across the value chain.
Stage 3 – Market estimation: top-down and bottom-up sizing, and data triangulation.
Stage 4 – Forecasting: factor-based projection of segment, regional and country markets.
Stage 5 – Validation and reporting: cross-checking of totals and segment splits, and preparation of the final report.
Secondary Research
Secondary research was used to build an understanding of the market, identify participants and collect data for market sizing. Sources relevant to agricultural biologicals and microbial crop protection included:
Industry associations: biological crop protection and biostimulant associations (such as the Biological Products Industry Alliance, the International Biocontrol Manufacturers Association, the European Biostimulants Industry Council and CropLife International) for adoption trends and policy positions.
Government and regulatory bodies: pesticide and bio-input registration databases and decisions published by the U.S. EPA, Health Canada’s PMRA, the European Commission and EFSA, Brazil’s Ministry of Agriculture and Livestock (MAPA), India’s Central Insecticides Board & Registration Committee and China’s Ministry of Agriculture and Rural Affairs.
Agricultural statistics: crop area, production and organic farming statistics from national agriculture ministries and statistical agencies.
Company filings: annual reports, investor presentations, product labels, technical bulletins and press releases of crop protection and biological companies.
Trade journals and scientific literature: agricultural trade publications and peer-reviewed research on B. velezensis strains, mode of action, formulation and field efficacy.
Paid databases: company financial databases, trade databases and agricultural input market databases.
Primary Research
Primary research was conducted to validate secondary findings, obtain qualitative insights and refine market estimates. Interviews were carried out by telephone, video conference and e-mail with participants on both the supply and demand sides.
Supply side: product managers, R&D and regulatory specialists, and sales and marketing executives at biological and crop protection companies, contract fermentation manufacturers and formulation specialists.
Demand side: distributors and agricultural retailers, crop advisers and agronomists, seed companies, cooperatives and large commercial growers of fruits, vegetables, cereals and other crops.
Objectives: to validate market size and segment splits, understand pricing and application rates, assess adoption barriers and purchase criteria, and capture views on regulatory developments and future demand.
Market Size Estimation
Top-down approach: the overall agricultural biologicals and biofungicide markets were used as the starting point. The share attributable to Bacillus-based products, and within it to B. velezensis strains, was estimated using product registration data, company portfolio analysis and expert input. The resulting global value was then allocated to regions, countries and segments.
Bottom-up approach: country-level demand was estimated from the area under relevant crops, the share of treated area, typical application rates and the average selling price of B. velezensis products for each formulation and application method. Country values were aggregated to regional and global totals.
Data triangulation: results from the two approaches were compared and reconciled with supply-side information on company revenues and product sales. Where discrepancies arose, additional primary interviews were used to resolve them, and the final estimates were checked to ensure that segment, country and regional values sum to the global total in every year.
Forecasting Methodology
Forecasts for 2026–2032 were prepared using a factor-based model applied to the 2025 base-year estimates. The model considers:
Macroeconomic factors such as agricultural GDP, farm income, crop prices and currency movements.
Crop area and production trends for fruits and vegetables, cereals and grains, and other crops.
Regulatory developments affecting synthetic fungicides and the registration of microbial products.
Growth of organic and residue-managed production and retailer residue requirements.
Product launches, formulation improvements and the expansion of seed-treatment and in-furrow use.
Adoption curves for biologicals in each region, based on current penetration and channel development.
Each factor was assigned an impact for the short, medium and long term, and the resulting growth rates were applied to segment and country markets. The forecasts were reviewed with industry experts and adjusted where necessary.
Assumptions and Limitations
All values are in nominal USD at manufacturer selling prices; exchange-rate movements are not separately modelled.
Products registered under earlier taxonomic names (B. amyloliquefaciens or B. subtilis) are included where the strain has been assigned to B. velezensis.
For multi-active products, value is attributed to the market where B. velezensis is a declared active ingredient.
No major disruption to global agricultural trade or input supply chains is assumed over the forecast period.
Regulatory frameworks are assumed to evolve in line with current policy direction; unexpected changes could alter regional growth.
On-farm multiplication of microbial products, which is significant in some countries, is difficult to measure and is excluded from commercial market value.
Company revenue data are not available at the B. velezensis product level; segment estimates therefore rely on triangulation and expert input.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Bacillus velezensis market is moderately fragmented. A group of global crop protection and biosolutions companies holds a significant share of branded product sales in North America and Europe, while a large number of regional biological companies, particularly in Brazil, China and India, compete with locally registered strains. Competition centres on strain performance and differentiation, breadth of registrations across crops and countries, formulation quality and shelf life, field-trial evidence, and access to distribution channels and seed-treatment partners.
The competitive structure has been changing rapidly. Large companies have acquired biological businesses or product rights to accelerate portfolio development, while specialist companies have expanded through partnerships with distributors and seed companies. Because several leading strains were originally registered as B. amyloliquefaciens or B. subtilis and have since been reassigned to B. velezensis on genomic grounds, competitors are increasingly emphasising strain-specific data, modes of action and agronomic results rather than species names in their marketing.
Key Player Positioning
Based on product portfolio, geographic reach, registrations and strategic activity, the companies profiled in this study can be grouped as leaders, challengers and niche players.
Leaders
BASF SE (Germany): BASF markets Serifel and related products based on strain MBI600, originally registered as Bacillus amyloliquefaciens MBI600, for fruits, vegetables and specialty crops, and uses the same strain in its Integral Pro seed treatment for oilseed rape and sunflower in Europe. BASF reported group sales of EUR 59.7 billion in 2025, with the Agricultural Solutions segment contributing EUR 9,587 million. Its strategy is to combine biological and chemical solutions within integrated crop programmes and seed treatments.
Bayer AG (Germany): Bayer's Serenade biofungicide family is based on Bacillus strain QST 713, which is registered as B. subtilis but which genomic studies have reported as B. velezensis. Bayer reported group sales of EUR 45.6 billion in 2025, of which Crop Science contributed EUR 21.6 billion. Bayer pursues biologicals through in-house products and partnerships, including its 2022 partnership with Ginkgo Bioworks covering Bayer's West Sacramento biologics research site.
Syngenta Group (Switzerland): Syngenta Biologicals markets Certano, a B. velezensis (CNPSo 3602) product acquired from Biotrop's Rudder brand in 2022 and launched for sugarcane in Brazil. Syngenta Group reported 2025 sales of USD 28.4 billion and double-digit growth in its biologicals business, supported by production sites in Brazil, Italy, India and Norway and a newly operational facility in Orangeburg, South Carolina.
FMC Corporation (U.S.): FMC's Ethos XB and Ethos Elite LFR combine bifenthrin with B. velezensis strain RTI301 and B. subtilis strain RTI477 for at-plant use in corn, soybean, cotton, peanuts and vegetables. FMC reported 2025 revenue of USD 3.47 billion and in February 2026 announced an exploration of strategic options, including a possible sale of the company.
Novonesis (Denmark): Formed in 2024 through the merger of Novozymes and Chr. Hansen, Novonesis markets Taegro and Taegro 2 biofungicides based on strain FZB24, a strain historically designated B. subtilis var. amyloliquefaciens that is now grouped with B. velezensis. The company reported 7% organic sales growth in 2025 and annual sales of approximately EUR 4 billion. Its strategy centres on microbial and enzymatic biosolutions across agriculture, food and industry.
Challengers
Certis Biologicals (U.S.): A wholly owned subsidiary of Mitsui & Co., Certis Biologicals markets Double Nickel LC and Double Nickel 55, based on strain D747, for vegetables, fruits, nuts and vines. In March 2024 it acquired the biofungicides Howler and Theia and related assets from AgBiome. Revenue is not disclosed separately from Mitsui & Co.
ProFarm Group / Bioceres Crop Solutions (U.S./Argentina): ProFarm, the biologicals business formed after Bioceres Crop Solutions acquired Marrone Bio Innovations in 2022, markets Stargus biofungicide based on strain F727, which received Canadian registration in January 2023. Bioceres Crop Solutions reported revenue of USD 335.3 million for the fiscal year ended 30 June 2025.
Koppert (Netherlands): Koppert is a family-owned biological crop protection company with a strong presence in Europe and Brazil. In September 2026 it launched Macan, a B. velezensis-based biofungicide for target spot (Corynespora cassiicola) in cotton, soybean, corn and beans in Brazil. Its most recent disclosed revenue is approximately EUR 435 million, and HAL Investments acquired a minority shareholding in 2024.
Niche Players
Biotrop (Brazil): Biotrop is a Brazilian biological inputs company with a microbial collection of more than 4,000 isolates and products for nematode, disease and insect control. It has been controlled by BioFirst (formerly Biobest) since 2023, following an agreement to acquire 85% of the company for approximately USD 569 million. Biotrop reported revenue of BRL 760 million in 2024.
ABiTEP GmbH (Germany): Based in Berlin, ABiTEP markets RhizoVital 42, based on the B. velezensis model strain FZB42, as a plant-strengthening and soil-conditioning product in Europe and, through distributors, in other markets including Australia. ABiTEP is privately held and does not publish revenue.
Competitor Dashboard
The dashboard below rates each profiled company on four parameters relevant to competitiveness in the Bacillus velezensis market. Ratings are qualitative analyst assessments.
Threat of New Entrants – Medium
Fermentation technology is widely available and many B. velezensis strains are described in public literature, lowering technical barriers.
Registration costs, the time required to build efficacy data and the need for distribution access create meaningful barriers in regulated markets.
Supportive bio-input regulations in some emerging markets are encouraging local entrants.
Bargaining Power of Suppliers – Low
Fermentation media and formulation inputs are commodity materials with many suppliers.
Most established companies own their strains, reducing dependence on external strain providers.
Contract fermentation capacity is available in most major regions.
Bargaining Power of Buyers – Medium
Large distributors and cooperatives have negotiating power and can switch between biological brands.
Growers in high-value horticulture are less price-sensitive because of residue and export requirements.
Differentiated strains with proven efficacy reduce buyer power for leading products.
Threat of Substitutes – High
Synthetic fungicides remain cheaper per hectare and more consistent under high disease pressure.
Other biological agents such as B. subtilis, Trichoderma spp., Pseudomonas spp. and botanical extracts compete for the same uses.
Resistant crop varieties and cultural practices can reduce the need for disease control products.
Competitive Rivalry – High
Many global and regional companies offer Bacillus-based biofungicides, leading to strong competition on efficacy claims and price.
Large crop protection companies use bundled offers and broad distribution to win share.
Rapid product launches and acquisitions increase competitive intensity.
Threat of New Entrants: Medium; Low technical barriers, but registration and distribution access are significant.
Bargaining Power of Suppliers: Low; Commodity inputs; proprietary strains held in-house.
Bargaining Power of Buyers: Medium; Consolidated distribution offset by product differentiation.
Threat of Substitutes: High; Synthetic fungicides and other biological agents.
Competitive Rivalry: High; Large number of participants and frequent launches.
Market estimates by geography (2032)
InsightNorth America leads with $150.15M by 2032, while Asia Pacific is projected to grow fastest at a 12.1% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $72.65M | $106.45M | $150.15M | 7.5% | 28% |
| Europe | $49.95M | $81.51M | $132.36M | 10.2% | 25% |
| Asia Pacific | $35.75M | $63.43M | $112.10M | 12.1% | 21% |
| Latin America | $43.05M | $72.20M | $120.72M | 10.9% | 22% |
| Middle East & Africa | $8.39M | $13.80M | $23.61M | 10.9% | 4% |
| Total | $209.79M | $337.39M | $538.94M | 9.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$538.94M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Wettable Powder | $223.66M | 8.7% | 42% |
| Liquid | $203.72M | 11.1% | 38% |
| Granules | $111.56M | 10.4% | 21% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Bacillus Velezensis Market covering market dynamics, competitive landscape, and strategic outlook.
The Bacillus Velezensis Market market is projected to reach $538.94M by 2032, growing at 9.9% CAGR. The Wettable Powder segment holds the largest share.
The Bacillus velezensis market is influenced by the broader shift in agriculture from purely chemical crop protection towards integrated programmes that combine synthetic and biological inputs. This chapter assesses the macro and micro factors that affect market growth, followed by the main drivers, restraints, opportunities, trends and challenges. The impact scores presented in the growth factor analysis are analyst assessments, based on secondary research and industry interviews, of the strength of each factor's influence on the market on a scale of 1 to 10.
Regulatory Pressure on Synthetic Fungicides
Regulators in several major markets have withdrawn or restricted widely used synthetic fungicides, creating demand for alternatives with a favourable toxicological profile. In the European Union, the approvals of chlorothalonil and mancozeb were not renewed in 2019 and 2020 respectively, and other actives face stricter hazard-based criteria under Regulation (EC) No 1107/2009. Lower maximum residue limits in importing markets, together with private retailer standards that cap the number of detectable residues, have increased the cost of relying solely on chemical programmes for export-oriented fruit and vegetable producers. B. velezensis products generally carry short or no pre-harvest intervals and are commonly exempt from residue tolerances, which allows growers to use them close to harvest and to rotate them with chemical fungicides to manage resistance. This regulatory environment is a central driver of the strong position of the Fruits & Vegetables segment, which accounted for USD 139.60 Million in 2025, and it is expected to remain a significant growth factor throughout the forecast period.
Expansion of Organic and Integrated Pest Management Programmes
The area under certified organic agriculture continues to expand in Europe, North America and parts of Asia and Latin America, while integrated pest management (IPM) has become a standard requirement in public policy and in the sustainability programmes of food companies. In the European Union, the Farm to Fork Strategy set a target of 25% of agricultural land under organic farming by 2030, and IPM is mandatory for professional users under the Sustainable Use Directive. Microbial products such as B. velezensis are among the few tools available for disease control in certified organic systems and are increasingly used in conventional IPM programmes to reduce chemical loads. Their dual action as biocontrol agents and plant-growth promoters adds value for growers seeking both disease suppression and improved root development, supporting demand across soil, seed and foliar applications.
Integration of Biologicals into Seed-Treatment and In-Furrow Programmes
Crop protection companies and seed companies are incorporating Bacillus strains into seed-treatment packages and at-planting products for corn, soybean, cotton, wheat and other broad-acre crops. Examples include FMC's Ethos Elite LFR, a combination of bifenthrin with B. velezensis strain RTI301 and B. subtilis strain RTI477 for in-furrow use in the U.S., and BASF's Integral Pro seed treatment based on strain MBI600, registered in France for sunflower from the 2026 sowing season. Seed treatment allows microbial actives to reach very large areas at low application rates and fits existing grower practices, which reduces the adoption barrier for biologicals in row crops. This explains why Seed Treatment is the fastest-growing application method, rising from USD 83.76 Million in 2025 to USD 178.66 Million in 2032 at a CAGR of 11.40%.
Investment and Consolidation in Agricultural Biologicals
Investment in biological crop inputs has continued through acquisitions, new production capacity and portfolio expansion. Bioceres Crop Solutions completed the acquisition of Marrone Bio Innovations in 2022, Biobest (now BioFirst) agreed in 2023 to acquire 85% of Brazilian biologicals company Biotrop for approximately USD 569 million, Certis Biologicals acquired biofungicide assets from AgBiome in 2024, and Syngenta Group reported a new biologicals production facility in Orangeburg, South Carolina, as operational in its 2025 results. These investments bring stronger distribution, registration capability and fermentation capacity to B. velezensis products, accelerating their commercial availability in more crops and countries.
Liquid and Fertiliser-Compatible Formulations
Advances in formulation are allowing manufacturers to supply concentrated liquid suspensions of B. velezensis spores with longer shelf lives and compatibility with liquid fertilisers, seed-treatment polymers and drip irrigation. These formulations reduce application steps for growers and support the use of B. velezensis in fertigation and in-furrow programmes. Liquid is the fastest-growing formulation segment, projected to grow from USD 97.72 Million in 2025 to USD 203.72 Million in 2032.
Expansion in Asia Pacific and Latin America
Asia Pacific and Latin America combine large cultivated areas, high disease pressure and supportive policy for biological inputs. Brazil's Law No. 15,070 of December 2024 created a dedicated legal framework for bio-inputs, including on-farm production, while India and China have programmes to reduce chemical pesticide use and promote biological alternatives. Asia Pacific is projected to add USD 61.84 Million between 2025 and 2032, and Latin America USD 62.09 Million.
Combination Products and Multi-Functional Biologicals
B. velezensis strains with both disease-suppression and growth-promotion activity can be combined with chemical fungicides, insecticides, other microorganisms or biostimulants to create differentiated products that deliver more consistent outcomes. Combination products allow crop protection companies to extend the life cycle of existing chemistry, address resistance management, and position biologicals within mainstream programmes for cereals, oilseeds and row crops.
Variable Field Performance
The efficacy of B. velezensis depends on the bacterium's ability to colonise roots or leaf surfaces and to produce antimicrobial metabolites, which can vary with soil type, temperature, moisture, UV exposure and the native microbial community. Under high disease pressure, biological products often deliver lower or less consistent control than synthetic fungicides and are therefore positioned as programme partners rather than stand-alone solutions. Inconsistent results in early adoption can discourage growers, particularly in broad-acre crops where margins per hectare are low.
Registration Complexity and Cost
Microbial active ingredients require dossiers covering strain identity, genetic characterisation, metabolite profile, pathogenicity, and environmental fate, and approval timelines can extend over several years. Requirements differ between countries, and the taxonomic reclassification of strains originally registered as B. amyloliquefaciens or B. subtilis creates additional complexity in labelling and in mutual recognition of data. For smaller biological companies, these costs limit the number of countries in which a strain can be registered.
Limited Awareness and Price Sensitivity in Emerging Markets
In many emerging agricultural economies, smallholder farmers have limited access to technical advice on biological products and are sensitive to per-hectare costs. Variable product quality, including from unregistered or on-farm multiplied products, can undermine confidence in the category.
Challenge: Quality Control and On-Farm Production
On-farm multiplication of microbial products, particularly in Brazil, offers growers lower costs but raises concerns about contamination and inconsistent strain identity. The development of quality standards under new bio-input regulations will be important for maintaining grower trust in commercial products.
Challenge: Demonstrating Return on Investment
Growers and distributors increasingly expect consistent yield or quality benefits to justify the cost of biological products. Building multi-season field evidence across crops and geographies remains a challenge, particularly for smaller suppliers.
Trend: Genome-Based Strain Selection and Characterisation
Whole-genome sequencing has become standard for characterising commercial strains, supporting regulatory dossiers, confirming taxonomy and identifying gene clusters for lipopeptides and polyketides. Companies increasingly screen large strain libraries for specific traits such as rhizosphere competence, stress tolerance and metabolite profiles, shortening development timelines.
Trend: Entry of Large Crop Protection Companies into Biologicals
Major crop protection companies are building dedicated biological units and acquiring product rights, as seen in Syngenta's acquisition of the B. velezensis-based product Certano from Biotrop's Rudder brand in 2022 and its subsequent launch for sugarcane in Brazil. This trend is increasing marketing investment and channel access for B. velezensis products.
The B. velezensis value chain extends from strain discovery to the grower. Value is concentrated at the strain ownership, formulation and registration stages, where proprietary know-how and regulatory approvals create barriers to entry.
B. velezensis products are regulated as microbial pesticides (plant protection products) where they carry disease-control claims, and in some countries as biostimulants, biofertilisers or soil amendments where claims are limited to plant growth. The main frameworks in major regions are summarised below.
April 2022: BASF SE; Product Launch; Introduced Serifel biofungicide (strain MBI600) in Argentina for strawberries and raspberries, with further crops planned.
July 2022: Bioceres Crop Solutions; Acquisition; Completed the acquisition of Marrone Bio Innovations, bringing products including Stargus (strain F727) into its ProFarm biologicals business.
2022: Syngenta Group; Acquisition; Acquired Certano, a B. velezensis (CNPSo 3602) product, from Biotrop’s Rudder brand.
April 2022: Bayer AG; Partnership; Announced an agricultural biologicals partnership with Ginkgo Bioworks, including the transfer of Bayer’s West Sacramento biologics research site and team.
January 2023: ProFarm Group; Registration; Health Canada’s PMRA published Registration Decision RD2023-01 for strain F727 and Stargus biofungicide.
September 2023: Biobest (BioFirst); Acquisition; Agreed to acquire an 85% stake in Brazilian biologicals company Biotrop for approximately USD 569 million.
November 2023: FMC Corporation; Product Launch; Announced Ethos Elite LFR (bifenthrin + B. velezensis RTI301 + B. subtilis RTI477), with limited commercial availability in 2024 and full launch in 2025.
November 2023: Syngenta Group; Product Launch; Promoted Certano in Brazil as its first biological for sugarcane, with bionematicide, biofungicide and growth-promoter activity.
January 2024: Novonesis; Merger; Novozymes and Chr. Hansen completed their merger to form Novonesis, combining their microbial biosolutions portfolios, including Taegro.
March 2024: Certis Biologicals; Acquisition; Acquired the Howler and Theia biofungicides and related assets from AgBiome.
2024: Koppert; Investment; HAL Investments acquired a minority shareholding in Koppert.
November 2025: BASF SE; Registration; Announced the French registration of Integral Pro (strain MBI600) seed treatment for sunflower, available from the 2026 sowing season.
2025: Syngenta Group; Expansion; Brought a new biologicals production facility in Orangeburg, South Carolina, into operation.
February 2026: FMC Corporation; Strategic Review; Announced an exploration of strategic options, including a possible sale of the company.
September 2026: Koppert; Product Launch; Launched Macan, a B. velezensis-based biofungicide for target spot in cotton, soybean, corn and beans, in Brazil.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 108 companies operating in the Bacillus Velezensis Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
FMC Corporation is a Philadelphia-based, pure-play crop-protection company and one of the tier-one research-based agrochemical innovators, alongside Syngenta, Bayer, BASF and Corteva. It discovers, develops, manufactures and markets insecticides, herbicides, fungicides and "Plant Health" products (biologicals, crop nutrition, seed treatment) through distributors, retailers, cooperatives and, increasingly, direct-to-grower channels in Brazil. Its economic franchise was built on the diamide insecticides acquired from DuPont in 2017: Rynaxypyr® (~USD 0.8bn of FY2025 sales) and Cyazypyr® (~USD 0.4bn). Both have now lost core patent protection. FMC is therefore in a deep transition. FY2025 revenue fell to USD 3.47bn and the company booked a USD 2.24bn GAAP loss. It has cut the dividend 86%, fallen to junk credit status, and in 2026 raised capital through asset sales, a Corteva licence and a 20% equity stake sale to Tessenderlo Group. The equity case now rests on four new-mode-of-action active ingredients: Isoflex®, fluindapyr, Dodhylex™ and rimisoxafen. --- ### Company's own description (FY2025 10-K, paraphrased) FMC describes itself as a global agricultural sciences company that supplies farmers with innovative solutions to increase the productivity and resilience of their land, and states that it operates in a single business segment. It develops, markets and sells all three major classes of crop-protection chemicals (insecticides, herbicides and fungicides), together with biologicals, crop nutrition and seed-treatment products grouped as "Plant Health." The 10-K calls FMC a "tier-one leader" in agrochemicals, positioned through technology, geographic balance and crop diversity. For 2026 it sets four operational priorities: - strengthening the balance sheet; - improving competitiveness of the core portfolio; - managing the post-patent Rynaxypyr® transition; - supporting the growth of new active ingredients. ### Value-chain position FMC is a discovery-to-formulation innovator that relies heavily on outsourcing. It owns large-scale AI plants in: - Mobile, Alabama (USA) - Manati, Puerto Rico - Jinshan, China - Rønland, Denmark - Panoli, India It also sources "critical intermediates and finished products" largely from third parties in China and India (10-K FY2025 risk factors). Downstream, it sells through: - distributors, retailers and cooperatives in all four regions; - direct sales to large growers in Brazil, an expanding channel cited as a Q4 FY2026 growth driver; - alliance partners, including diamide partners on "cost-plus" contracts. ### Customer types and end-markets Customers are agricultural distributors and retailers, co-ops, large growers (Brazil), and other agrochemical companies that buy diamide AI under supply contracts. End-markets are row crops (soybean, corn, cotton, sugarcane, rice, cereals) and specialty crops (fruits, vegetables, tree nuts). Non-crop uses (pest control, turf) were largely exited with the sale of the Global Specialty Solutions business in November 2024. Demand is seasonal. Northern-hemisphere demand runs March–September, weighting Q1/Q2. Southern-hemisphere demand runs July–February, weighting Q3, Q4 and Q1 (10-K FY2025). ### Independent characterization FMC is a mid-sized research-based agrochemical company. It has a disproportionately concentrated franchise: the diamides were roughly 35% of FY2025 GAAP revenue (USD ~1.2bn of USD 3.47bn). The company is now caught between generic-driven price deflation on its legacy molecules and a still-sub-scale new-AI portfolio (USD ~200M in FY2025). It also faces an unusually leveraged balance sheet for a company of its size. Its strategy has shifted from "growth and returns" (2021–2023) to "survival and re-base" (2025–2026): - monetize IP through partners (Corteva); - shrink the manufacturing footprint (Project Foundation); - exit structurally unprofitable markets (India commercial); - recapitalize via a strategic minority investor (Tessenderlo).
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
4 interactive charts drawn from the Bacillus Velezensis Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Bacillus Velezensis Market By Application Method
Global Bacillus Velezensis Market By Crop Type
Global Bacillus Velezensis Market By Formulation
Global Bacillus Velezensis Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
